0.25
+0.0198(+8.44%)
Currency In USD
| Previous Close | 0.23 |
| Open | 0.24 |
| Day High | 0.26 |
| Day Low | 0.24 |
| 52-Week High | 1.93 |
| 52-Week Low | 0.22 |
| Volume | 652,172 |
| Average Volume | 1.26M |
| Market Cap | 18.44M |
| PE | -0.34 |
| EPS | -0.74 |
| Moving Average 50 Days | 0.3 |
| Moving Average 200 Days | 0.7 |
| Change | 0.02 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $24.46 as of December 26, 2024 at a share price of $0.245. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 2 years ago, it would be worth $134.4 as of December 26, 2024 at a share price of $0.245.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100’s long-te
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
GlobeNewswire Inc.
Dec 02, 2024 12:00 PM GMT
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 -
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome.